Samsung BioLogics participates in ‘Bio Japan 2024’
Securing ultra-high concentration (200mg/ml) formulation development technology and data
Risk of development failure reduced by adding ‘concentration gate check step’
Vice President Min Ho-seong “Strengthening CDO competitiveness through innovative technology and services”
Launch of the 4th CDO platform this year
Samsung BioLogics has introduced a new high-concentration formulation development platform.
Samsung BioLogics announced on the 14th that it launched the high-concentration formulation development platform ‘S-HiCon’ through ‘BIO JAPAN 2024′ held in Yokohama, Japan last week. At the Bio Japan exhibition, brochures and banners were used to actively promote S-Hycon to visitors, and on the 14th, a webinar video explaining the platform was posted on Samsung BioLogics’ official website. It can be found in the Webinars section of the Newsroom Bio Resource Center (Science&Technology) menu.
Samsung BioLogics explained that S-Hycon was launched to preemptively respond to the recently increasing demand in the high-concentration drug market. High-concentration formulation medicines are used in the development of subcutaneous injections and ocular injections because the drug administration dose required to exert the same effect compared to low-concentration formulations is small. Additionally, customized treatment is possible according to symptoms. From the bio company’s perspective, storage and transportation costs can be reduced, and profits can be expected to improve.
In particular, in the process of developing a high-concentration formulation, problems arise in which viscosity increases and hydrogen ion concentration changes, but Samsung BioLogics solved these problems by selecting the right excipients that affect viscosity and hydrogen ion concentration control. In addition, data on the development of ultra-high concentration formulations of over 200 mg/ml were also obtained. Generally, the industry considers dosage forms over 150mg/ml to be high-concentration drugs. Dosages exceeding 200mg/ml are considered ultra-high concentration dosage forms.
Samsung BioLogics explained that the risk of failure in developing high-concentration formulations was minimized by adding a ‘concentration gate check step’ to check whether concentration is possible to the customer’s desired concentration before entering the full-scale formulation development stage.
With the launch of S-Hycon, Samsung BioLogics has further strengthened its CDO (Consignment Development) services. The number of CDO platforms launched this year has increased to four, and there are a total of nine technology platforms. Prior to S-Hycon, last month at the 2024 Bioprocess International, ‘S-AfuCHO’, which increases the anti-cancer effect of antibodies, and ‘S-OptiCharge’, a high-quality protein production support platform, were unveiled. . In June of this year, ‘S-Tensify’, a high-concentration cell culture development support platform, was launched at the 2024 Bio International Convention.
In order to respond to the evolving biopharmaceutical market, Samsung BioLogics plans to continuously strengthen its technological competitiveness not only by developing new platforms but also by utilizing and upgrading existing platforms.
Min Ho-seong, vice president and head of Samsung BioLogics CDO Development Center, said, “By providing formulation development services desired by customers from low to high concentrations, drugs of various formulations will be able to enter the market more quickly.” He added, “We will provide innovative solutions to provide customized services to customers.” “We plan to continue developing technology and services,” he said.
Kim Min-beom, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog